Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma

Sulis, E; Floris, C.; Sulis, Maria Luisa; Zurrida, Stefano; Piro, S; Pintus, A.; Contu, L.

doi:10.1016/0277-5379(89)90217-4

Cited by 46 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[47][48][49][50] Intralesional injections of chemotherapeutic agents such as vinblastine have been used to treat extensive oral lesions and may, in fact, represent the treatment of choice. 47 Treatment of oral Kaposi sarcoma by intralesional injection using other classes of chemotherapeutic agents has been assessed and varying degrees of success with these agents have been reported, e.g., interferon 55,56 and sclerosing agents such as 3% sodium tetradecyl sulphate. 47 In addition, some systemic absorption of the drug is likely to occur and may induce systemic side-effects, including neutropenia.…”

Section: Treatmentmentioning

confidence: 99%

Oral Kaposi Sarcoma Associated with Severe Alveolar Bone Loss: Case Report and Review of the Literature

Lausten

Ferguson²,

Barker³

et al. 2003

Journal of Periodontology

View full text Add to dashboard Cite

Although AIDS-related oral Kaposi sarcoma is a relatively common finding, erosion of subjacent alveolar bone is uncommon. Treatment of the tumor with subsequent dental reconstruction can be complicated by the severe lack of bone, surgical perforation of the maxillary sinus, and lack of stable teeth to serve as abutments. Significant advances in understanding the pathogenesis of AIDS-related Kaposi sarcoma have occurred in the last decade. HHV-8 and various inflammatory cytokines have been implicated in the pathogenesis and are likely to become the primary targets for therapeutic intervention.

show abstract

Section: Treatmentmentioning

confidence: 99%

Oral Kaposi Sarcoma Associated with Severe Alveolar Bone Loss: Case Report and Review of the Literature

Lausten

Ferguson²,

Barker³

et al. 2003

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…Topical injection of the sclerosing agent sodium tetradecyl sulfate is an alternative therapy for the management of oral KS with mild adverse reactions 79,80 . Intralesional injection of interferon‐α has also been reported in earlier trials 81,82 …”

Section: Discussionmentioning

confidence: 96%

Gingival Involvement in a Case Series of Patients With Acquired Immunodeficiency Syndrome‐Related Kaposi Sarcoma

Kalpidis

Lysitsa

Lombardi

et al. 2006

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…This therapy is relatively inexpensive, easy to administer, well tolerated and effective, and renders recurrences unlikely . The efficacy of intralesional interferon‐α (IFN‐α) in the treatment of OKS has also been documented . Limited and focal mucocutaneous KS may also be treated effectively with topical liquid nitrogen …”

Section: Treatmentmentioning

confidence: 99%

“…41 The efficacy of intralesional interferon-a (IFN-a) in the treatment of OKS has also been documented. 42 Limited and focal mucocutaneous KS may also be treated effectively with topical liquid nitrogen. 43 Oral KS is highly radiosensitive.…”

Section: Treatmentmentioning

confidence: 99%

Oral Kaposi's sarcoma: a review and update

Fatahzadeh

Schwartz

2013

Int J Dermatology

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) is an important mucocutaneous neoplasm with four well-known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with AIDS-KS. The latter may signal undiagnosed HIV infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral KS (OKS) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non-pigmented to brownish-red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. OKS needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. KS may flare as part of the immune reconstitution inflammatory syndrome in HIV patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of KS and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post-transplant OKS but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for HHV-8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post-transplant OKS.

show abstract

Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma

Cited by 46 publications

References 6 publications

Oral Kaposi Sarcoma Associated with Severe Alveolar Bone Loss: Case Report and Review of the Literature

Oral Kaposi Sarcoma Associated with Severe Alveolar Bone Loss: Case Report and Review of the Literature

Gingival Involvement in a Case Series of Patients With Acquired Immunodeficiency Syndrome‐Related Kaposi Sarcoma

Oral Kaposi's sarcoma: a review and update

Contact Info

Product

Resources

About